These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30984311)

  • 1. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study.
    Salgueiro M; Stribos M; Zhang LF; Stevens M; Awad ME; Elsalanty M
    EPMA J; 2019 Mar; 10(1):21-29. PubMed ID: 30984311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of drug holiday before tooth extraction on the development of medication-related osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates.
    Karaca Ç; Topaloğlu-Yasan G; Adiloğlu S; Usman E
    J Korean Assoc Oral Maxillofac Surg; 2023 Apr; 49(2):68-74. PubMed ID: 37114444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of drug holiday on preventing medication-related osteonecrosis of the jaw in osteoporotic rat model.
    Zhu WY; Yang WF; Wang L; Lan X; Tao ZY; Guo J; Xu J; Qin L; Su YX
    J Orthop Translat; 2023 Mar; 39():55-62. PubMed ID: 36721766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia.
    Friedlander AH; Chang TI; Hazboun RC; Garrett NR
    J Oral Maxillofac Surg; 2015 Sep; 73(9):1735-40. PubMed ID: 25863230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    Marx RE; Cillo JE; Ulloa JJ
    J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.
    Awad ME; Sun C; Jernigan J; Elsalanty M
    J Am Dent Assoc; 2019 Aug; 150(8):664-675.e8. PubMed ID: 31256803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Drug Holiday Affect Jaw Trabeculation in Medication Related Osteonecrosis of the Jaw? - A Pilot Study.
    Panneer-Selvam N; Alamoudi A; Riley Iii J; Katz J
    J Clin Exp Dent; 2022 Apr; 14(4):e341-e348. PubMed ID: 35419174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone necrosis around dental implants: A patient treated with oral bisphosphonates, drug holiday and no risk according to serum CTX.
    Flichy-Fernández AJ; González-Lemonnier S; Balaguer-Martínez J; Peñarrocha-Oltra D; Peñarrocha-Diago MA; Bagán-Sebastián JV
    J Clin Exp Dent; 2012 Feb; 4(1):e82-5. PubMed ID: 24558532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday.
    Hamid A; Thomas S; Bell C; Gormley M
    Br J Oral Maxillofac Surg; 2023 Apr; 61(3):227-232. PubMed ID: 36935312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical protocol in patients at risk for bisphosphonate osteonecrosis of the jaws: clinical use of serum telopetide CTX in preventive monitoring of surgical risk.
    Carini F; Saggese V; Porcaro G; Barbano L; Baldoni M
    Ann Stomatol (Roma); 2012 Jan; 3(1):31-6. PubMed ID: 22783453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study.
    Hutcheson A; Cheng A; Kunchar R; Stein B; Sambrook P; Goss A
    J Oral Maxillofac Surg; 2014 Aug; 72(8):1456-62. PubMed ID: 24793621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.
    Traboulsi-Garet B; Jorba-García A; Camps-Font O; Alves FA; Figueiredo R; Valmaseda-Castellón E
    Clin Oral Investig; 2022 Mar; 26(3):2371-2382. PubMed ID: 35124731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of the bone markers osteocalcin and C-terminal telopeptide for jaw osteonecrosis in high-risk prostate cancer patients on bisphosphonate therapy: A prospective study.
    Delaka A; Mourmouras N; Zervou-Valvi F; Stravodimos K; Anastasiou I; Delakas D
    Arch Esp Urol; 2019 Nov; 72(9):948-954. PubMed ID: 31697256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw.
    Peisker A; Raschke GF; Fahmy MD; Guentsch A; Roshanghias K; König KC; Schultze-Mosgau S
    J Craniofac Surg; 2018 Mar; 29(2):e137-e140. PubMed ID: 29215447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors associated to Medication-Related Osteo Necrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study.
    Cuozzo A; Iorio-Siciliano V; Vaia E; Mauriello L; Blasi A; Ramaglia L
    J Stomatol Oral Maxillofac Surg; 2022 Nov; 123(6):616-621. PubMed ID: 35609780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?
    O'Connell JE; Ikeagwani O; Kearns GJ
    Ir J Med Sci; 2012 Jun; 181(2):237-42. PubMed ID: 22223192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.